Navigation Links
HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
Date:3/6/2013

SAN DIEGO, March 6, 2013 /PRNewswire/ -- HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, "Zhangjiang Biotech Pharmaceutical Base").  HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations.  This new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Founded in 1996 and supported jointly by the Ministry of Science and Technology, the Ministry of Health, SFDA, Chinese Academy of Sciences and Shanghai Municipal Government, Zhangjiang Biotech Pharmaceutical Base focuses on the development of innovations in biotechnology and pharmaceutical industries.   As the core district of Shanghai National Bio-Industry Base with the nickname "Zhangjiang Pharmaceutical Valley", after more than 15 years of development it has attracted more than 300 life science companies, research institutes and related service organizations, both domestic and international, and formed a comprehensive bio-pharmaceutical innovation system and industrial clusters.

The partnership will enable HUYA and Zhangjiang Biotech Pharmaceutical Base to collaborate on promoting new drug development worldwide.  Zhangjiang Biotech Pharmaceutical Base will be able to consult with HUYA's team of experts in drug development and globalization.  In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at Zhangjiang Biotech Pharmaceutical Base and provide support and assistance as needed.

"HUYA is delighted to work with the prestigious Zhangjiang Biotech Pharmaceutical Base in a partnership that aims to advance the global development of innovative pharmaceutical products from China," said Clement Gingras , HUYA's Chief Technical Officer and COO, China.  "We are very excited about this partnership and look forward to fruitful collaborations in the years to come." 

Senior management of Zhangjiang Biotech Pharmaceutical Base also expressed optimism about this collaboration:  "Our goal is to become a top-rank pharmaceutical development base in Asia, and build a world-renowned biomedical innovation platform.  We hope that HUYA will help accelerate the global reach of innovations originated from 'Zhangjiang Pharmaceutical Valley' by providing expertise on global pharmaceutical development." 

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With eight offices strategically located across China, the most comprehensive Chinese compound database in the world, and a growing number of collaboration agreements with premier Chinese research and development organizations, HUYA occupies a unique position with regards to the China bio-pharmaceutical industry.  Its strategy to identify and license novel Chinese compounds, and to offer Western pharmaceutical companies efficient and comprehensive access to therapeutic innovation in China, means the company can enable efficient global development.  HUYA has become a champion in guiding China's biomedical innovations into the worldwide marketplace.  HUYA is jointly headquartered in Shanghai and in San Diego, California.  More information is available at www.huyabio.com.

ABOUT ZHANGJIANG BIOTECH PHARMACEUTICAL BASE

Since the establishment of State Biotech and Pharmaceutical Industrial Base (Shanghai) in Zhangjiang in 1996 and implementation of the strategic policy of "Focus on Zhangjiang", Zhangjiang Biotech Pharmaceutical Base has gone through tremendous growth and now houses more than 300 institutions and enterprises, including national research institutes, R&D headquarters of multinational pharmaceutical companies, many domestic pharmaceutical companies, CROs, and public service platforms.  It has become one of the landmark biopharma park and industrial cluster, known for having the highest density of research and development institutions, the highest capability for innovation and the most prominent result for new drug development in China. More information is available at http://www.zjbpb.com/web/index.asp.

Shanghai Pharma Engine Co., Ltd, a wholly owned subsidiary of Zhangjiang Biotech and Pharmaceutical Base Development Co., is a state-level biopharmaceutical incubator, providing technical, contract research and investment consultation services.  More information is available at http://www.zhangjiang.net/tabid/182/ArticleID/462/Default.aspx.

CONTACT

Clement Gingras
CTO and COO, China
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
2. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
3. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
4. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
5. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
6. Dr. Susan Froshauer to join Connecticut bioscience team at CURE
7. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
8. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
9. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... acquire a majority ownership interest in Dental Cremer S.A., ... Brazil . --> ... is the dental distribution business of Cremer S.A. With ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... in the United States District Court for the District of ... (the "Class") consisting of all persons or entities who purchased ... (NASDAQ: INSY ) from March 3, 2015 through January ... certain of its officers with violations of the Securities Exchange ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... Illinois (PRWEB) , ... February 05, 2016 , ... ... and independent PROSHRED franchises from across the country gathered at the La Valencia ... recognize top performers. PROSHRED Chicago was named the year’s most outstanding franchise, ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled ... provide the most effective tattoo removal today, Dr. Bentkover is the only doctor in ... Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) as ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Health and ... more relevant to individuals in the event they are experiencing an illness. Migraines are ... Those Americans that are afflicted with migraines would not wish the pain on their ...
Breaking Medicine News(10 mins):